ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX) announced today that it has entered into an exclusive worldwide license agreement with Cardiff University in Wales, United Kingdom and Katholieke Universiteit in Leuven, Belgium for intellectual property covering a series of highly potent hepatitis C virus (HCV) polymerase inhibitors in exchange for an upfront license fee, future milestone payments and royalties on future net sales. Additional financial details of the transaction were not disclosed.
